BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC has announced a recent transaction by Non-Executive Director Robert Hawkins, involving a ‘Bed and ISA’ transfer of 20,000 Ordinary Shares. Hawkins executed the sale and immediate repurchase of the shares at different prices, maintaining a 0.39% interest in the company. BiVictriX focuses on developing innovative, next-generation cancer therapeutics with its proprietary Bi-Cygni® ADCs, aiming to enhance treatment efficacy and safety.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
